Abstract:Tumor angiogenesis plays a pivotal role in the progress of tumor. Among the various endogenous angiogenic inhibitors discovered, the human plasminogen kringle 5 (K5) has been demonstrated to be a potential inhibitor of the proliferation and migration of vascular endothelial cells in vitro. The replication-incompetent adenovirus (Ad) vector Adeno-X-CMV-K5 (Ad-K5) (where CMV is cytomegalovirus) was constructed and its antiangiogenic effect was tested on vascular endothelial cell and tumor cell. For the construction, the K5 cDNA was fused in-frame with human plasminogen signal sequence and inserted into the eukaryotic expression vector pcDNA3 to form pcDNA3K5. The recombinant plasmid was subcloned into the shuttle plasmid pShuttle under the control of the constitutive CMV immediate-early promoter. The plasmid carrying the cDNA for K5 (pShuttleKS) was then recombined with the Adeno-X viral DNA and transformed into E. coli DH5alpha. The resultant recombinant plasmid pAd-K5 was transfected into human embryonic kidney (HEK) 293 cells with liposome. The adenovirus expressing human plasminogen kringle 5 (Ad-K5) was successfully packaged and propagated in 293 cells, as detected by the cytopathic effect (CPE) on the cells, and the viral titer in the supernatant was 5 x 10(8) pfu/mL by plaque assay. Both human umbilical vein endothelial cell line ECV304 and human breast carcinoma cell line MDA-MB-231 were infected with Ad-K5 and Ad-LacZ, which was used the negative control, and assayed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Compared with uninfected control and Ad-LacZ infected control, Ad-K5 infected group at 80 MOI (multiplicity of infection) significantly inhibited ECV304 proliferation; the difference between uninfected control and Ad-LacZ infected control was not significant. In contrast, there was no significant difference in the proliferation of MDA-MB-231 among all the treatments. In addition, the Ad-K5 at 100 MOI inhibited the differentiation and tube formation of ECV304 on ECMatrix gel. These results suggested that the recombinant replication-defective Adenovirus expressing human plasminogen kringle 5 inhibited the proliferation, differentiation and tube formation of ECV304 and had no effect on the proliferation of MDA-MB-231. Adenovirus mediated human plasminogen kringle 5 gene therapy may be a potential treatment of cancer through angiogenesis inhibition.

Extracellular Domain of Kinase Domain Region Mediated by Adeno-Associated Virus Inhibits Growth and Angiogenesis of Bladder Cancer in Balb-c Mice.

EDARADD Silencing Suppresses the Proliferation and Migration of Bladder Cancer Cells

[Effects of Vascular Endothelial Growth Factor (VEGF) Antisense Oligodeoxynucleotide on Mrna and Expression of VEGF, Flt-1, and Kinase Insert Domain Containing Receptor and VEGF Excretion in Human Gallbladder Carcinoma Cells].

Arg-Gly-Asp (Rgd)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice

AAV-mouse DNase I sustains long-term DNase I expression in vivo and suppresses breast cancer metastasis

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

[Preparation and Functional Study of an Adenovirus Vector Expressing Human Plasminogen Kringle 5 Gene].

[Inhibition of K562 Cell Growth and Tumor Angiogenesis in Nude Mice by Antisense VEGF(121) Cdna Transfection].

The Inhibitory Effect of Conditionally Replicating Adenovirus Combined with Mitomycin on the Proliferation of Bladder Cancer Cells

Acetyl-11-Keto-Beta-Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice.

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

A Hybrid Protein Comprising ATF Domain of Pro‐uk and VAS, an Angiogenesis Inhibitor, is a Potent Candidate for Targeted Cancer Therapy

Inhibition of Growth and Metastases of Inoculated Human Prostate Cancer in Nude Mice by Antisense Vascular Endothelial rowth Factor

RKTG Inhibits Angiogenesis by Suppressing MAPK-mediated Autocrine VEGF Signaling and is Downregulated in Clear-Cell Renal Cell Carcinoma

Adenovirus-mediated Transfer of P53 and P16 Inhibiting Proliferating Activity of Human Bladder Cancer Cell EJ in Vitro and in Vivo

Inhibition of K562 Leukemia Angiogenesis and Growth by Expression of Antisense Vascular Endothelial Growth Factor (VEGF) Sequence

Intratumoral Injection of Antisense VEGF Plasmid Suppresses K562 Cells Growth in Nude Mice and Increases Apoptosis of Leukemia Cells

The Effect of Anti-Vegf Antiserum on the Progression of Bladder Cancer in Mouse Model